rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-1S-67-74rsp-2256Research ArticleОБЗОРЫПРИМЕНЕНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ ДЛЯ ЛЕЧЕНИЯ АКСИАЛЬНЫХ СПОНДИЛОАРТРИТОВ, ВКЛЮЧАЯ АНКИЛОЗИРУЮЩИЙ СПОНДИЛИТ, МОНИТОРИНГ ЭФФЕК ТИВНОСТИ И БЕЗОПАСНОСТИ (ПРОЕК Т РЕКОМЕНДАЦИЙ ГРУППЫ ЭКСПЕРТОВ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ СПОНДИЛОАРТРИТОВ)USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS, MONITORING THEIR EFFICACY AND SAFETY (DRAFT GUIDELINES OF THE EXPERT SPONDYLOARTHRITIS DIAGNOSIS AND TREATMENT GROUP)ГайдуковаИ. З.GaidukovaI. Z.РебровА. П.RebrovA. P.ОттеваЭ. Н.OttevaE. N.БадокинВ. В.BadokinV. V.БочковаА. Г.BochkovaA. G.БугроваО. В.BugrovaO. V.ГодзенкоА. А.GodzenkoA. A.ДубиковА. А.DubikovA. A.ДубининаТ. В.DubininaT. V.ИвановаО. Н.IvanovaO. N.КоротаеваТ. В.KorotaevaT. V.ЛапшинаС. А.LapshinaS. A.НесмеяноваО. Б.NesmeyanovaO. B.НикишинаИ. П.NikishinaI. P.РаскинаТ. А.RaskinaT. A.РумянцеваО. А.RumyantsevaO. A.СмирновА. В.SmirnovA. V.СиталоА. В.SitaloA. V.ЭрдесШ. В.ErdesSh. F.123456_57@mail.ruСаратовский государственный медицинский университет имени В.И. Разумовского Минздрав России, СаратовРоссияV.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, SaratovRussian FederationИнститут повышения квалификации специалистов здравоохранения, Минздрав Хабаровского края, ХабаровскРоссияInstitute for Advanced Training of Healthcare Specialists, Ministry of Health of the Khabarovsk Territory, KhabarovskRussian FederationРоссийская медицинская академия постдипломного образования, Минздрав России, МоскваРоссияRussian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowRussian FederationМедицинский центр «Агат», ЕгорьевскРоссияAgat Medical Center, Egoryevsk, Moscow RegionRussian FederationОренбургский государственный медицинский университет, Минздрав России, ОренбургРоссияRussian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowRussian FederationТихоокеанский государственный медицинский университет, Минздрава России, ВладивостокРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian FederationНаучно-исследовательский институт ревматологии имени В.А. Насоновой, МоскваRussian FederationВоронежская областная клиническая больница №1, ВоронежРоссияVoronezh Regional Clinical Hospital One, VoronezhRussian FederationНаучно-исследовательский институт ревматологии имени В.А. Насоновой, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian FederationКазанский государственный медицинский университет, Минздрава России, КазаньРоссияKazan State Medical University, Ministry of Health of Russia; KazanRussian FederationЧелябинская областная клиническая больница, ЧелябинскРоссияChelyabinsk Regional Clinical Hospital, ChelyabinskRussian FederationКемеровская государственная медицинская академия, Минздрав России, КемеровоРоссияKemerovo State Medical Academy, Ministry of Health of Russia, KemerovoRussian FederationОбщество взаимопомощи при болезни Бехтерева, МоскваРоссияSociety of Mutual Assistance in Bechterew’s Disease, MoscowRussian Federation201616092016541Sприложение 16774Copyright © Гайдукова И.З., Ребров А.П., Оттева Э.Н., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.А., Дубинина Т.В., Иванова О.Н., Коротаева Т.В., Лапшина С.А., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.В., 20162016Гайдукова И.З., Ребров А.П., Оттева Э.Н., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.А., Дубинина Т.В., Иванова О.Н., Коротаева Т.В., Лапшина С.А., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.В.Gaidukova I.Z., Rebrov A.P., Otteva E.N., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.A., Dubinina T.V., Ivanova O.N., Korotaeva T.V., Lapshina S.A., Nesmeyanova O.B., Nikishina I.P., Raskina T.A., Rumyantseva O.A., Smirnov A.V., Sitalo A.V., Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2256

Представлен проект рекомендаций, разработанных группой экспертов  по изучению спондилоартритов (ЭкСпА)  по поручению Ассоциации ревматологов России.  Рекомендации включают основные  положения по применению нестероидных противовоспалительных препаратов  при аксиальных спондилоартритах, включая анкилозирующий спондилит, содержат указания  по длительности  их применения, описывают  возможную тактику ведения пациентов в наиболее частых клинических ситуациях и предпочтительный алгоритм оценки  эффективности и безопасности лечения.

The paper gives the draft guidelines elaborated  by the Expert Spondyloarthritis  Diagnosis and Treatment Group  by order of the Association of Rheumatologists  of Russia. The guidelines include the essentials of how to use nonsteroidal  anti-inflammatory drugs in axial spondyloarthrititides, including ankylosing spondylitis, contain  instructions  for how long they should be administered, and describe possible patient  management tactics in the most common  clinical situations and a preferential  algorithm for evaluating the efficiency and safety of treatment.

спондилоартритыаксиальные спондилоартритыанкилозирующий спондилитнестероидные противовоспалительные препаратыэффективность терапииремиссиябезопасность терапииspondyloarthritisaxial spondyloarthritisankylosing spondylitisnonsteroidal anti-inflammatory drugsefficiency of therapyremissionsafety of therapyReferencesЭрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660.Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660.Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860Miedany YE. Treat to target in spondyloarthritis: the time has come. Curr Rheumatol Rev. 2015;10(2):87-93. doi: 10.2174/1573397110666140301000430Miedany YE. Treat to target in spondyloarthritis: the time has come. Curr Rheumatol Rev. 2015;10(2):87-93. doi: 10.2174/1573397110666140301000430Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol. 2015;42(4):654-64. doi: 10.3899/jrheum.141000Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol. 2015;42(4):654-64. doi: 10.3899/jrheum.141000Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200-9. doi: 10.1093/rheumatology/keu461Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200-9. doi: 10.1093/rheumatology/keu461Ward MM. Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014;33(6):739-40. doi: 10.1007/s10067-014-2660-9Ward MM. Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014;33(6):739-40. doi: 10.1007/s10067-014-2660-9Wendling D, Lukas C, Paccou J, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):6-14. doi: 10.1016/j.jbspinWendling D, Lukas C, Paccou J, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):6-14. doi: 10.1016/j.jbspinVan der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of antiTNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. doi: 10.1136/ard.2011.151563Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of antiTNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. doi: 10.1136/ard.2011.151563Van den Berg R, Baraliakos X, Braun J, et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford). 2012.51(8):1388-96. doi: 10.1093/rheumatology/kes066Van den Berg R, Baraliakos X, Braun J, et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford). 2012.51(8):1388-96. doi: 10.1093/rheumatology/kes066Kim H, Lee J, Ahnet JK, et al. Predictive factors of radiographic progression in ankylosing spondylitis. Korean J Intern Med. 2015;30(3):391-7. doi: 10.3904/kjim.2015.30.3.391Kim H, Lee J, Ahnet JK, et al. Predictive factors of radiographic progression in ankylosing spondylitis. Korean J Intern Med. 2015;30(3):391-7. doi: 10.3904/kjim.2015.30.3.391Гайдукова ИЗ, Ребров АП. Эффективность и безопасность различных режимов назначения эторикоксиба у пациентов с аксиальным спондилоартритом, включая анкилозирующий спондилит. Терапевтический архив. 2015;87(3):77-82 [Gaydukova IZ, Rebrov AP. Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis. Terapevticheskii Arkhiv. 2015;87(3):77-82 (In Russ.)]. doi: 10.17116/terarkh201587377-82Гайдукова ИЗ, Ребров АП. Эффективность и безопасность различных режимов назначения эторикоксиба у пациентов с аксиальным спондилоартритом, включая анкилозирующий спондилит. Терапевтический архив. 2015;87(3):77-82 [Gaydukova IZ, Rebrov AP. Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis. Terapevticheskii Arkhiv. 2015;87(3):77-82 (In Russ.)]. doi: 10.17116/terarkh201587377-82Каратеев АЕ, Эрдес ШФ. Применение нестероидных противовоспалительных препаратов при анкилозирующем спондилите: долго и упорно! Терапевтический архив. 2014;86(11):123-7 [Karateev AE, Erdes ShF. Use of nonsteroidal anti-inflammatory drugs in case of ankylosing spondylitis: Long and persistently! Terapevticheskii Arkhiv. 2014;86(11):123-7 (In Russ.)].Каратеев АЕ, Эрдес ШФ. Применение нестероидных противовоспалительных препаратов при анкилозирующем спондилите: долго и упорно! Терапевтический архив. 2014;86(11):123-7 [Karateev AE, Erdes ShF. Use of nonsteroidal anti-inflammatory drugs in case of ankylosing spondylitis: Long and persistently! Terapevticheskii Arkhiv. 2014;86(11):123-7 (In Russ.)].Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drugfree remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807-18. doi: 10.1016/j.berh.2014.10.005Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drugfree remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807-18. doi: 10.1016/j.berh.2014.10.005Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93-5. doi: 10.1136/annrheumdis-2011-200798Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93-5. doi: 10.1136/annrheumdis-2011-200798Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015;11(8):935-46. doi: 10.1586/1744666X.2015.1052795Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015;11(8):935-46. doi: 10.1586/1744666X.2015.1052795Гайдукова ИЗ, Ребров АП, Нам ИФ, Кирсанова НВ. Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. Терапевтический архив. 2014;86(2):42-7 [Gaidukova IZ, Rebrov AP, Nam IF, Kirsanova NV. Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis including ankylosing spondylitis. Terapevticheskii Arkhiv. 2014;86(2):42-7 (In Russ.)].Гайдукова ИЗ, Ребров АП, Нам ИФ, Кирсанова НВ. Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. Терапевтический архив. 2014;86(2):42-7 [Gaidukova IZ, Rebrov AP, Nam IF, Kirsanova NV. Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis including ankylosing spondylitis. Terapevticheskii Arkhiv. 2014;86(2):42-7 (In Russ.)].Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71(8):1278-88. doi: 10.1136/ard.2011.150680Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis. 2012;71(8):1278-88. doi: 10.1136/ard.2011.150680Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-98. doi: 10.1002/art.33465Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-98. doi: 10.1002/art.33465Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369-74. doi: 10.1136/ard.2010.145995Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369-74. doi: 10.1136/ard.2010.145995Song IH, Hermann KG, Haibel H, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis. 2011;70(7):1257-63. doi: 10.1136/ard.2010.147033Song IH, Hermann KG, Haibel H, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis. 2011;70(7):1257-63. doi: 10.1136/ard.2010.147033Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis – evidence for major individual variations in a large proportion of patients. J Rheumatol. 2009;36(5):997-1002. doi: 10.3899/jrheum.080871Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis – evidence for major individual variations in a large proportion of patients. J Rheumatol. 2009;36(5):997-1002. doi: 10.3899/jrheum.080871Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003 Feb;62(2):127-32. doi: 10.1136/ard.62.2.127Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003 Feb;62(2):127-32. doi: 10.1136/ard.62.2.127Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987;8(1):71-85.Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987;8(1):71-85.Russell RI. Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S14-8.Russell RI. Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S14-8.Chan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complicationsreview and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61. doi: 10.1111/j.1365-2036.2004.01935.xChan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complicationsreview and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61. doi: 10.1111/j.1365-2036.2004.01935.xDubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197-208. doi: 10.1111/j.0269-2813.2004.01834.xDubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197-208. doi: 10.1111/j.0269-2813.2004.01834.xRussell RI. Helicobacter pylori eradication may reduce the risk of gastroduodenal lesions in chronic NSAID users. Ital J Gastroenterol Hepatol. 1997;29(5):465-9.Russell RI. Helicobacter pylori eradication may reduce the risk of gastroduodenal lesions in chronic NSAID users. Ital J Gastroenterol Hepatol. 1997;29(5):465-9.McCarthy DM. Helicobacter pylori infection and gastroduodenal injury by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1991;187:91-7. doi: 10.3109/00365529109098230McCarthy DM. Helicobacter pylori infection and gastroduodenal injury by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1991;187:91-7. doi: 10.3109/00365529109098230Greenland P, Alpert JS, Beller GA, et al. ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010;2010(122):e584–e636. doi: 10.1016/j.jacc.2010.09.001Greenland P, Alpert JS, Beller GA, et al. ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010;2010(122):e584–e636. doi: 10.1016/j.jacc.2010.09.001Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul;144(1):95-100. doi: 10.1067/mhj.2002.123317Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul;144(1):95-100. doi: 10.1067/mhj.2002.123317Definition of Cronic Kidney Disease. Kidney Int Suppl (2011). 2013;3(1):19-62. doi: 10.1038/kisup.2012.64Definition of Cronic Kidney Disease. Kidney Int Suppl (2011). 2013;3(1):19-62. doi: 10.1038/kisup.2012.64Каратеев АЕ, Успенский ЮП, Пахомова ИГ и др. Прием НПВП и патология пищевода: связь с основными симптомами гастроэзофагеальной рефлюксной болезни (ГЭРБ), частота развития и факторы риска эрозивного эзофагита. Экспериментальная и клиническая гастроэнтерология. 2008;(3):11-6 [Karateev AE, Uspenskii YuP, Pakhomova IG, et al. Receiving NSAIDs and pathology of the esophagus: association with the main symptoms of gastroesophageal reflux disease (GERD), the incidence of and risk factors for erosive esophagitis. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2008;(3):11-6 (In Russ.)].Каратеев АЕ, Успенский ЮП, Пахомова ИГ и др. Прием НПВП и патология пищевода: связь с основными симптомами гастроэзофагеальной рефлюксной болезни (ГЭРБ), частота развития и факторы риска эрозивного эзофагита. Экспериментальная и клиническая гастроэнтерология. 2008;(3):11-6 [Karateev AE, Uspenskii YuP, Pakhomova IG, et al. Receiving NSAIDs and pathology of the esophagus: association with the main symptoms of gastroesophageal reflux disease (GERD), the incidence of and risk factors for erosive esophagitis. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2008;(3):11-6 (In Russ.)].Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients withankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015 May 13;10(5):e0126347. doi: 10.1371/journal.pone.0126347.eCollection2015.Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients withankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015 May 13;10(5):e0126347. doi: 10.1371/journal.pone.0126347.eCollection2015.Гайдукова ИЗ, Акулова АИ, Апаркина АВ и др. Приверженность к лечению и эффективность терапии при разных режимах мониторинга активности у пациентов с аксиальным спондилоартритом. Клиническая медицина. 2014;92(10):60-5 [Gaidukova IZ, Akulova AI, Aparkina AV, et al. Adherence to treatment and the effectiveness of treatment with different modes of activity monitoring in patients with axial spondyloarthritis. Klinicheskaya Meditsina = Clinical Medicine. 2014;92(10):60-5 (In Russ.)].Гайдукова ИЗ, Акулова АИ, Апаркина АВ и др. Приверженность к лечению и эффективность терапии при разных режимах мониторинга активности у пациентов с аксиальным спондилоартритом. Клиническая медицина. 2014;92(10):60-5 [Gaidukova IZ, Akulova AI, Aparkina AV, et al. Adherence to treatment and the effectiveness of treatment with different modes of activity monitoring in patients with axial spondyloarthritis. Klinicheskaya Meditsina = Clinical Medicine. 2014;92(10):60-5 (In Russ.)].Brown TJ, Hooper L, Elliott RA, et al. A comparison of the costeffectiveness of five strategies for the prevention of non-steroidal anti-inflammatorydrug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006;10(38):iii-iv, xi-xiii, 1-183.Brown TJ, Hooper L, Elliott RA, et al. A comparison of the costeffectiveness of five strategies for the prevention of non-steroidal anti-inflammatorydrug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006;10(38):iii-iv, xi-xiii, 1-183.Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi: 10.1186/s12891-015-0532-3Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi: 10.1186/s12891-015-0532-3Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29;104:108-14. doi: 10.1016/j.phrs.2015.12.026 [Epub ahead of print].Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29;104:108-14. doi: 10.1016/j.phrs.2015.12.026 [Epub ahead of print].Rosen E, Tsesis I, Vered M. U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal anti-inflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective. Refuat Hapeh Vehashinayim (1993). 2015 Oct;32(4):6-10, 25. HebrewRosen E, Tsesis I, Vered M. U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal anti-inflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective. Refuat Hapeh Vehashinayim (1993). 2015 Oct;32(4):6-10, 25. HebrewHsu CC, Wang H, Hsu YH, et al. Use of nonsteroidal antiinflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/hypertensionaha.114.05105Hsu CC, Wang H, Hsu YH, et al. Use of nonsteroidal antiinflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/hypertensionaha.114.05105Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16;10(4):e0122899. doi: 10.1371/journal.pone.0122899Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16;10(4):e0122899. doi: 10.1371/journal.pone.0122899Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956-65. doi: 10.3748/wjg.v20.i38.13956Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956-65. doi: 10.3748/wjg.v20.i38.13956Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55. doi: 10.1093/fampra/cms086Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55. doi: 10.1093/fampra/cms086Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747.Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747.

The authors declare that there are no conflicts of interest present.